Fig. 4.

Liver-specific knockdown of perilipin 2 increases VLDL-TG secretion in Cideb^−/− mice without affecting apoB synthesis and secretion. (A) Knockdown of perilipin 2 led to significant increases in VLDL-TAG secretion in wild-type and Cideb^−/− mice. After treatment with Ad-shPerilipin 2 or Ad-ctrl shRNA for a week, the Cideb^−/− and wild-type mice were fasted for 12 h and injected with 500 mg/kg body weight Triton WR-1339. Blood samples were collected at the indicated time points after Triton WR-1339 injection (n = 4). *P < 0.05, **P < 0.01, ***P < 0.001. Data are the means ± SEM. (B) Representative photographs of the plasma samples of four samples from each group treated with Triton WR-1339 for 4 h. (C) Levels of liver apoB-100/apoB-48 and MTP in Cideb^−/− mice treated with Ad-shPerilipin 2 and Ad-ctrl shRNA. (D) Levels of plasma apoB-100/apoB-48 in Cideb^−/− mice treated with Ad-shPerilipin 2 and Ad-ctrl shRNA. Serum was collected 12 h after fasting. Albumin stained with Coomassie Brilliant Blue G-250 was used as a loading control. (E) The rates of apoB-100/apoB-48 secretion in Cideb^−/− mice with or without perilipin 2 knockdown were similar. The mice were injected with Triton WR-1339 after 12 h of fasting, and blood was collected at the indicated durations. Levels of plasma apoB-100/apoB-48 were visualized by immunoblotting (left panel). The apoB-100/apoB-48 levels were determined semiquantitatively using Bio-Rad Quantity One software (right panel).